Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19

Bruna Lo Sasso, PhD,1,2 Caterina Maria Gambino, PhD,1 Nicola Scichilone, MD,3 Rosaria Vincenza Giglio, PhD,1 Giulia Bivona, MD,1 Concetta Scaczone, BS,1 Roberto Muratore, BS,2 Salvatore Milano, BS,2 Mario Barbagallo, MD,4 Luisa Agnello, PhD,1 Marcello Ciaccio, MD1,2,*

Laboratory Medicine 2021;52:493-498
DOI: 10.1093/labmed/lmab032

ABSTRACT

Objective: The aim of the study was to assess the role of midregional proadrenomedullin (MR-proADM) in patients with COVID-19.

Methods: We included 110 patients hospitalized for COVID-19. Biochemical biomarkers, including MR-proADM, were measured at admission. The association of plasma MR-proADM levels with COVID-19 severity, defined as a requirement for mechanical ventilation or in-hospital mortality, was evaluated.

Results: Patients showed increased levels of MR-proADM. In addition, MR-proADM was higher in patients who died during hospitalization than in patients who survived (median, 2.59 nmol/L; interquartile range, 2.3–2.95 vs median, 0.82 nmol/L; interquartile range, 0.57–1.03; P < .0001). Receiver operating characteristic curve analysis showed good accuracy of MR-proADM for predicting mortality. A MR-proADM value of 1.73 nmol/L was established as the best cutoff value, with 90% sensitivity and 95% specificity (P < .0001).

Conclusion: We found that MR-proADM could represent a prognostic biomarker of COVID-19.

Keywords: biomarker, COVID-19, inflammation, MR-proADM, respiratory disease

COVID-19 is caused by SARS-CoV-2, which primarily infects the respiratory system in humans. It is characterized by a broad spectrum of clinical manifestations with varying degrees of severity, from asymptomatic form to pneumonia, which can evolve into acute respiratory distress syndrome and multiorgan failure syndrome, until death.1-4

SARS-CoV-2 internalization occurs by the viral spike glycoprotein that binds to angiotensin-converting enzyme 2 (ACE2), which is mainly expressed on type II alveolar epithelial cells, myocardial cells, proximal tubule cells of the kidney, bladder urothelial cells, and enterocytes.5,6 This interaction results in the downregulation of ACE2 expression and excessive angiotensin production, enhancing an inflammatory response that contributes to acute organ injury.7

The clinical course of the disease is unpredictable, and there is an urgent need for biomarkers that could reliably stratify patients into different classes of risk. Early identification of hospitalized patients who are more vulnerable to clinical deterioration could guide clinicians for risk stratification and monitoring.

The hallmark of SARS-CoV-2 infection is the activation of the immune system, which can lead to an uncontrolled and...
generalized inflammatory response and to the so-called cytokine storm. Indeed, patients with COVID-19 have significantly increased circulating levels of inflammatory biomarkers, such as interleukin (IL)-6, C-reactive protein (CRP), and procalcitonin (PCT). Moreover, several biochemical parameters, such as D-dimer, cardiac troponin, and homocysteine, are altered. These biomarkers have been associated with disease severity and mortality. However, there is ongoing research for biomarkers to better define the biochemical phenotype of COVID-19 patients to improve their management.

Midregional proadrenomedullin (MR-proADM) is a surrogate biomarker of adrenomedullin (ADM), a 52–amino acid peptide belonging to the Calc gene family. Under physiological conditions, ADM levels are very low. Several factors, including catecholamines, hypoxia, oxidative stress, inflammatory mediators, and cytokines, induce their increase. Thus, it has been evaluated in several inflammatory conditions. However, the measurement of ADM has several technical issues, such as a short half-life and rapid degradation by proteases. The more stable MR-proADM provides a solution to these problems. The latter is secreted in equimolar amounts with ADM and is more stable in vitro. Moreover, it can be easily measured on a fully automated platform.

Research has recently proposed MR-proADM as a biomarker of organ failure. Specifically, increased MR-proADM levels have been associated with short- and long-term mortality in patients with community-acquired pneumonia and sepsis. In addition, MR-proADM has emerged as a prognostic biomarker in critically ill patients admitted to the intensive care unit (ICU) independently by their underlying clinical conditions. Considering that patients with COVID-19 are at high risk of developing organ failure, MR-proADM could represent a useful prognostic biomarker.

The aim of the present study was to evaluate the potential prognostic value of MR-proADM to predict in-hospital mortality in patients with COVID-19.

**Methods**

**Study Population**

In this retrospective observational study, we enrolled all consecutive adult patients admitted to the COVID-19 units at the University Hospital P. Giaccone in Palermo, Italy, from September to October 2020. A SARS-CoV-2 infection was confirmed by a positive real-time reverse-transcription polymerase chain reaction mainly using naso-oropharyngeal swabs, in accordance with guidelines.

Demographical and clinical information, including the length of stay (LOS), in-hospital mortality, and admission to ICU, was recorded for each patient. The primary endpoints for assessing COVID-19 severity were the requirement for mechanical ventilation and in-hospital mortality.

The local ethics committee approved the study, and all the clinical and biological assessments were carried out in accordance with the Declaration of Helsinki. For privacy respect, each patient was identified with an alphanumeric code. Informed consent was not required because the blood specimen used for study procedures was residual material that would have otherwise been discarded.

**Hematological and Biochemical Analysis**

All laboratory analyses were performed at the Laboratory Medicine Unit of the University Hospital P. Giaccone in Palermo. Routine hematological and biochemical parameters were measured upon admission. Specifically, hematological tests, including red and white blood cells, platelets, neutrophils, lymphocytes, and monocytes, were performed using the UniCel DxH 900 hematology analyzer (Beckman Coulter’s Inc., Brea, CA).

Serum biochemical parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, creatine kinase (CK), lactate dehydrogenase (LDH), serum creatinine (sCR), high-sensitivity troponin T (hs-TnT), vitamin D, high-sensitivity CRP, IL-6, and PCT were measured on the Cobas 8000 (Roche, Basel, Switzerland), according to the manufacturer’s procedures. The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology collaboration equation expressed for specified race, sex, and sCR in mg/dL.

After the routine analyses were performed, an aliquot of plasma was collected within 3 hours of blood collection and stored at –80°C. The MR-proADM was measured by the time-resolved amplified cryptate emission technology (TRACE-Kryptor MR-proADM; BRAHMS AG, Henningsdorf, Germany), as previously described. The MR-proADM
The assay has a limit of detection of 0.05 nmol/L and a limit of quantification of 0.23 nmol/L, as declared by the manufacturer.

### Statistical Analysis

Statistical analysis was performed using MedCalc v12.1.4.0 statistical software (MedCalc Software, Mariakerke, Belgium). Demographic and clinical characteristics were expressed as frequencies (percentage) for categorical data and median with interquartile ranges (IQR) for continuous data.

A Spearman correlation coefficient was used to assess the relationships between plasma MR-proADM levels and several clinical and laboratory parameters. Finally, receiver operating characteristic (ROC) curves with 95% confidence intervals (CI) were calculated to assess the prognostic ability of MR-proADM. A P value <.05 was considered statistically significant in all the calculations.

### Results

#### Demographic and Clinical Features

One hundred ten patients admitted to converted COVID-19 units for SARS-CoV-2 infection were included in the study. Demographic and baseline clinical characteristics of patients are shown in Table 1.

Overall, 92 (84%) patients had pneumonia, and none of the patients at admission required intubation; 60 (55%) had more severe infections and needed noninvasive ventilation with positive airway pressure, and 50 (45%) had moderate respiratory symptoms. The median LOS was 13 days (IQR, 8–19). According to the clinical course of the disease, 2 (2%) patients were transferred to the ICU, and 14 patients (13%) died during hospitalization. The median (IQR) time to death was 9 (8–10) days.

#### Laboratory Findings

Table 2 shows the laboratory test findings. In the overall study population, we observed lymphocytopenia (lymphocytes <1.50 × 10^3/μL). On admission, most patients showed normal levels of AST, ALT, total bilirubin, sCR, LDH, and CK. A weak increase in serum D-dimer and hs-TnT concentrations were observed in 37% and 51% of patients, with a median level of 850 ng/mL (IQR, 477–1420) and 19 pg/mL (IQR, 16–35), respectively. In addition, a moderate decrease in vitamin D levels in most patients (76%) was found, with a median level of 23 ng/mL (IQR, 15.5–30). Similarly, eGFR values were reduced in only 24% of patients.

As reported in Table 2, inflammation was the prominent feature of our studied population, with significantly higher CRP and IL-6 levels. In particular, CRP was >40 mg/L in nearly half of patients (47%), and IL-6 was elevated in 81 (74%) patients with a median level of 19 pg/mL (IQR, 7–38). The PCT was increased in 17 (15%) patients (median levels 0.103 ng/mL; IQR, 0.05–0.17).

In addition to classical inflammatory biomarkers, MR-proADM plasma levels were also significantly increased in 79 (72%) patients, with a median level of 0.93 nmol/L (IQR, 0.58–1.09).

We found that MR-proADM levels were correlated with biochemical parameters reflecting inflammation. In particular, we observed a statistically significant correlation between MR-proADM and CRP (r = .49; 95% CI, 0.30–0.64; P <.0001), LDH (r = .56; 95% CI, 0.39–0.69; P <.0001), IL-6 (r = .50; 95% CI, 0.29–0.66; P <.0001), PCT (r = .58; 95% CI, 0.39–0.73; P <.0001), and hs-TnT (r = .80; 95% CI, 0.68–0.88; P <.0001) values. Moreover, MR-proADM had a weakly positive correlation with total bilirubin (r = .28; 95% CI, 0.01–0.48; P = .01).

| Table 1. General Characteristics, Comorbidities and Clinical Outcomes in the Study Population (n = 110) |
|---------------------------------------------------------------|
| **Demographic Characteristics**                              |
| Median age, (IQR), y                                         | 62 (52–76) |
| Male sex, n (%)                                              | 61 (55)    |
| Comorbidities                                                |            |
| Chronic respiratory disease, n (%)                           | 93 (84)    |
| Chronic kidney disease, n (%)                                | 6 (5)      |
| Diabetes, n (%)                                              | 8 (7)      |
| Hypertension, n (%)                                          | 19 (17)    |
| Severe cardiovascular disease, n (%)                         | 2 (2)      |
| Hospital stay, median (IQR), d                               | 13 (8–19)  |
| Hospital discharge, n (%)                                    | 29 (26)    |
| ICU transfer, n (%)                                          | 2 (2)      |
| Death, n (%)                                                 | 14 (13)    |
| ICU, intensive care unit; IQR, interquartile range.          |            |

---
and sCR (r = .25; 95% CI, 0.04–0.45; P = .02) and a negative correlation with vitamin D (r = –.37; 95% CI, –0.61 to –0.07; P = .01). No significant correlation was found between MR-proADM and ALT (r = .007; 95% CI, –0.21 to 0.23; P = .95), AST (r = .18; 95% CI, –0.04 to 0.38; P = .10), and CK (r = –.01; 95% CI, –0.23 to 0.20; P = .91).

**MR-proADM in Risk Stratification of Patients with SARS-CoV-2**

We found that MR-proADM was significantly associated with in-hospital mortality but not with LOS (r = .19; 95% CI, –0.13 to 0.48; P = .23). Indeed, patients who died (n = 14) during hospitalization had higher MR-proADM levels than patients who survived (n = 96; median, 2.59; IQR, 2.3–2.95 nmol/L; range, 1.89–10.58 nmol/L vs median, 0.82; IQR, 0.57–1.03 nmol/L; range, 0.44–2.63 nmol/L; P < .0001). According to the ROC curve analysis, the area under the curve (AUC) of MR-proADM for predicting mortality was 0.95 (95% CI, 0.86–0.99; **Figure 1**). An MR-proADM value of 1.73 nmol/L was identified as the optimal cutoff value for mortality prediction, with 90% sensitivity and 95% specificity (P < .0001).

### Discussion

In this study, we sought to evaluate the prognostic value of MR-proADM in patients with COVID-19. Only a few studies have evaluated the role of such a biomarker in patients with SARS-CoV-2 infection.29,30

In our study, most patients showed altered levels of inflammatory biomarkers, such as lymphocytopenia, reduced vitamin D levels, and eGFR, along with increased D-dimer, hs-TnT, IL-6, CRP, and PCT levels, in accordance with the literature.10,31 Notably, MR-proADM was significantly increased in 72% of patients. In addition, nonsurvivors

| Table 2. Laboratory Findings of Study Population (n = 110) |
|-----------------|-----------------|
| **Median (IQR) Reference Interval** | **Hematological parameters** |
| **White blood cell count, 10³/μL** | 8.0 (5.96–10.8) 3.6–10.2 3.8–11.8 |
| **Neutrophils, 10³/μL** | 6.2 (3.90–8.90) 1.7–8.2 |
| **Lymphocytes, 10³/μL** | 0.90 (1.0–3.2) |
| **Monocytes, 10³/μL** | 0.55 (0.20–0.70) 0.2–1.1 |
| **Eosinophils, 10³/μL** | 0 (0–0.02) 0–0.5 |
| **Basophils, 10³/μL** | 0.01 (0–0.02) 0–0.1 |
| **Red cells, 10⁶/μL** | 4.5 (4.1–4.8) 4.0–5.6 3.6–4.9 |
| **Hemoglobin, g/dL** | 13.4 (12–14) 12.5–16.0 11.0–14.0 |
| **MCV, fL** | 85 (82–90) 75–95 |
| **MCH, pg** | 29 (28–31) 30–36 |
| **RDW, fL** | 42 (39–44) 36.5–50.3 |
| **Platelets, 10³/μL** | 222 (155–307) 150–400 |
| **Biochemical parameters** | **ALT, U/L** 34 (21–51) 0–41 |
| **AST, U/L** | 27 (20–40) 0–37 |
| **Bilirubin, mg/dL** | 0.6 (0–0.8) <1.20 |
| **CK, U/L** | 70 (41–151) 26–192 |
| **sCR, mg/dL** | 0.7 (0.55–0.8) 0.50–1.20 |
| **D-dimer, ng/mL** | 850 (477–1420) 0–800 |
| **eGFR, mL/min** | 82.5 (67–92.3) <90 |
| **LDH, U/L** | 228 (181–325) 50–250 |
| **hs-TnT, pg/mL** | 19 (16–35) <14 |
| **Vitamin D, ng/mL** | 23.0 (15.5–30) ≥30 |
| **Inflammatory parameters** | **CRP, mg/dL** 33 (18–79) <5 |
| **IL-6, pg/mL** | 19 (7–38) <7 |
| **PCT, ng/mL** | 0.103 (0.05–0.17) <0.05 |
| **MR-proADM, nmol/L** | 0.93 (0.58–1.09) <0.55 |

**ALT**, alanine aminotransferase; **AST**, aspartate aminotransferase; **CRP**, C-reactive protein; **CK**, creatine kinase; **eGFR**, estimated glomerular filtration rate; **hs-TnT**, high-sensitivity troponin T; **IL-6**, interleukin-6; **IQR**, interquartile range; **LDH**, lactate dehydrogenase; **MCH**, mean corpuscular hemoglobin; **MCV**, mean corpuscular volume; **MR-proADM**, midregional proadrenomedullin; **PCT**, procalcitonin; **RDW**, red cell distribution width; **sCR**, serum creatinine.

![Figure 1](https://example.com/figure1.png)

ROC curve analysis of MR-proADM for predicting in-hospital mortality. MR-proADM showed sensitivity of 90% and specificity of 95%; the cutoff value was 1.73 nmol/L. MR-proADM, midregional proadrenomedullin; ROC, receiver operating characteristic.
showed higher MR-proADM levels than survivors. The ROC analysis revealed a good accuracy of MR-proADM for predicting mortality with an AUC of 0.95 at a cutoff value of 1.73 nmol/L.

Finally, we found a significant correlation between MR-proADM and inflammatory biomarkers, as previously shown by studies performed in patients with other clinical conditions, such as pneumonia.32-36 Overall, our findings suggest that the measurement of MR-proADM upon hospital admission could provide important prognostic information in patients with COVID-19.

To date, the role of different biomarkers in COVID-19 management, from diagnosis to treatment monitoring, has been assessed.37 However, contrasting results have been achieved.38-40 Indeed, COVID-19 is a disease about which much is still unknown, and there is active research to understand its pathogenesis and consequently to identify useful biomarkers. Among all the biomarkers currently studied, a role for hypovitaminosis D has been reported. Recently, Hernández et al41 showed that more than 80% of patients hospitalized with COVID-19 had vitamin D deficiency, which was associated with inflammatory biomarkers. In accordance with such evidence, we found an association between reduced vitamin D levels and higher levels of MR-proADM. In addition, a recent review highlighted that approximately one-third of patients with COVID-19 showed neurological manifestations, particularly seizures and status epilepticus.32-45

In this study, we found an optimal MR-proADM cutoff value of 1.73 nmol/L, which is slightly lower than that established by Spoto et al29 (2 nmol/L) but higher than that reported by Gregoriano et al30 (0.93 nmol/L). Larger studies are required before introducing such a biomarker into clinical practice to confirm these preliminary findings and establish a unique cutoff value. Moreover, the mechanism underlying the increase of MR-proADM in patients with COVID-19 should be elucidated.

Our study presents some limitations. First, it is a single, monocenter, and retrospective study. Thus, it provides a snapshot of the biomarker within patients with COVID-19, allowing us to draw some conclusions mainly about the distribution of MR-proADM in our study population. In addition, the low rate of mortality could affect the robustness of the ROC curve analysis findings. Our strength is that we first evaluated the role of MR-proADM in a large population of patients with COVID-19.

**Conclusion**

The identification of biomarkers to define patients who are likely to deteriorate during their hospitalization could help clinicians to improve their clinical management. In this study, at hospital admission, patients with more severe COVID-19 showed higher levels of MR-proADM, together with other inflammatory biomarkers. Noteworthy, a variability in MR-proADM levels in COVID-19 patients exists. Our results agree with those of Spoto et al29 but are different from those of Gregoriano et al.30 who reported lower MR-proADM concentrations. Thus, further studies to determine a cutoff value are imperative.

Our findings encourage further investigation to confirm the usefulness of MR-proADM as a prognostic biomarker in patients with COVID-19. Such a biomarker can be easily and rapidly measured on a fully automated platform. Thus, MR-proADM could be part of a panel of biomarkers to evaluate the prognosis and assess the risk of developing complications.46-50

**References**

1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–473.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
3. Lai CC, Ko WC, Lee PI, Jean SS, Hsueh PR. Extra-respiratory manifestations of COVID-19. Int J Antimicrob Agents. 2020;56(2):106024.
4. Coz Yataco AO, Simpson SQ. Coronavirus disease 2019 sepsis: a nudge toward antibiotic stewardship. Chest. 2020;158(5):1833–1834.
5. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–637.
6. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185–192.
7. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
8. Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Ann J Pathol. 2007;170(4):1136–1147.
9. Ciaccio M, Agnello L. Biochemical biomarkers alterations in coronavirus disease 2019 (COVID-19). Diagnosis (Berl). 2020;7(4):365–372.
10. Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID-19—a systematic review. Life Sci. 2020;254:117788.

11. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-19 infection. Clin Chim Acta. 2020;508:1143–1144.

12. Ponti G, Runici C, Tomasi A. Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19. Med Hypotheses. 2020;143:109859.

13. Vivona N, Bivona G, Noto D, et al. C-reactive protein but not soluble CD40 ligand and homocysteine is associated to common atherosclerotic risk factors in a cohort of coronary artery disease patients. Clin Biochem. 2009;42(16–17):1713–1718.

14. Li J, Gong X, Wang Z, et al. Clinical features of familial clustering in patients infected with 2019 novel coronavirus in Wuhan, China. Virus Res. 2020;286:198043.

15. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(1):1018–1020.

16. Tang Y, Liu Z, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. J Intern Med. 2020;287(2):156–164.

17. Elsasser TH, Kahl S. Adrenomedullin has multiple roles in disease progression. J Vasc Res. 2002;39(4):250–257.

18. De La Torre-Prados MV, Garcia-De La Torre A, Engvall A, et al. Mid-regional pro-adrenomedullin as prognostic biomarker in septic shock. Minerva Anestesiol. 2016;82:763–766.

19. Agnello L, Bivona G, Parisi E, et al. Presepsin and midregional proadrenomedullin in pediatric oncologic patients with febrile neutropenia. Lab Med. 2020;51(8):585–591.

20. Spoto S, Fogolari M, De Florio L, et al. Procalcitonin and MR-pro-adrenomedullin combination in the etiological diagnosis and prognosis of sepsis and septic shock. Microbiol Pathog. 2019;137:103763.

21. Angeletti S, Spoto S, Fogolari M, et al. Diagnostic and prognostic role of procalcitonin (PCT) and MR-pro-adrenomedullin (MR-proADM) in bacterial infections. APMIS. 2015;123(9):740–748.

22. Valenzuela-Sánchez F, Valenzuela-Méndez B, Rodríguez-Gutierrez JF, Estella-García A, González-García MA. New role of biomarkers: mid-regional pro-adrenomedullin, the biomarker of organ failure. Ann Transl Med. 2016;4(17):255.

23. Spoto S, Nobile E, Canà EPR, et al. Best diagnostic accuracy of sepsis combining SIRS criteria or cSOFA score with procalcitonin and mid-regional pro-adrenomedullin outside ICU. Sci Rep. 2020;10(1):16605.

24. Bellia C, Agnello L, Lo Sasso B, et al. Mid-regional pro-adrenomedullin predicts poor outcome in non-selected patients admitted to an intensive care unit. Clin Chim Acta. 2019;497:549–555.

25. Krüger S, Ewig S, Giersdorf S, Hartmann O, Suttrop N, Welte T. German Competence Network for the Study of Community Acquired Pneumonia (CAPNETZ) Study Group. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: results from the German Competence Network. APMIS. 2015;123(9):740–748.

26. Saeed K, Wilson DC, Bloos F, et al. Correction to: The early identification of disease progression in patients with suspected infection presenting to the emergency department: a multi-centre derivation and validation study. Crit Care. 2019;23(1):255.

27. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance, 25 January 2020. https://apps.who.int/iris/handle/10665/330854. Accessed March 30, 2021.

28. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612. Published correction appears in Ann Intern Med. 2011;155(8):408.

29. Spoto S, Agrò FE, Sambuco F, et al. High value of mid-regional proadrenomedullin in COVID-19: a marker of widespread endothelial damage, disease severity and mortality. J Med Virol. Published online November 16, 2020. doi: 10.1002/jmv.28676.

30. Gregorriano C, Koch D, Kutz A, et al. The vasactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study. Clin Chem Lab Med. Published online January 8, 2021. doi: 10.1515/cclm-2020-1296.

31. Henry B, Cheryuyot I, Vikse J, et al. Lymphopenia and neutrophilia at admission predicts severity and mortality in patients with COVID-19: a meta-analysis. Acta Biomedi. 2020;9(1):e2000008.

32. Giulia B, Luca S, Concetta S, Bruna LS, Chiara B, Marcello C. Procalcitonin and community-acquired pneumonia (CAP) in children. Clin Chim Acta. 2015;451(Pt B):215–218. doi: 10.1016/j.cca.2015.09.031.

33. Agnello L, Bivona G, Di Gangi M, et al. Utility of serum procalcitonin and C-reactive protein in severity assessment of community-acquired pneumonia in children. Clin Biochem. 2016;49(1–2):47–50.

34. Florin TA, Ambroggio L, Brokamp C, et al. Proadrenomedullin predicts severe disease in children with suspected community-acquired pneumonia. Clin Infect Dis. Published August 6, 2020. doi: 10.1093/cid/ciaa1138.

35. Pilotto A, Dini S, Veronese N, et al. Multidimensional Prognostic Index and pro-adrenomedullin plasma levels as mortality risk predictors in older patients hospitalized with community-acquired pneumonia: a prospective study. Pannonia Med. 2018;60(3):80–85.

36. Kakareko K, Rydzewska-Rosolowska A, Rygasiwicz K, et al. Prognostic value of midregional proadrenomedullin in critically ill patients. Pol Arch Intern Med. 2019;129(10):673–678.

37. Lo Sasso B, Giglio RV, Gambino CM, et al. SARS-CoV-2: new perspectives for the clinical laboratory diagnostics. Biochimica Clinica. 2020;44(2):203–204.

38. Huang L, Zhao X, Qi Y, et al. Sepsis-associated severe interleukin-6 storm in critical coronavirus disease 2019. Cell Mol Immunol. 2020;17(10):1092–1094.

39. Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clin Chim Acta. 2020;58:1083–1089.

40. Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020;99(6):1205–1208.

41. Hernández JL, Nan D, Fernandez-Ayala M, et al. Vitamin D status in hospitalized patients with SARS-CoV-2 infection. J Clin Endocrinol Metab. 2021;106(8):el343–el353.

42. Narula N, Joseph R, Katyal N, et al. Seizure and COVID-19: association and review of potential mechanism. Neurol Psychiatry Brain Res. 2020;38:49–53.

43. Hollar A, Clemens Z, Kamondi A, Lakatos P, Szücs A. Correction of vitamin D deficiency improves seizure control in epilepsy: a pilot study. Epilepsy Behav. 2012;24(1):131–133.

44. Bivona G, Gambino CM, Iacollino G, Ciaccio M, Vitamin D and the nervous system. Neurol Res. 2019;41(8):827–835.

45. Bivona G, Lo Sasso B, Iacollino G, et al. Standardized measurement of circulating vitamin D [25(OH)D] and its putative role as a serum biomarker in Alzheimer’s disease and Parkinson’s disease. Clin Chim Acta. 2019;497:82–87.

46. Silberstein M. Correlation between premorbidity IL-6 levels and COVID-19 mortality: potential role for Vitamin D. Int Immunopharmacol. 2020;88:106995.

47. Bellia C, Zaininotto M, Cosima C, et al. Definition of the upper reference limit of glycated albumin in blood donors from Italy. Clin Chim Acta. 2019;451(Pt B):215–218. doi: 10.1016/j.cca.2015.09.031.

48. Parveen R, Sehar N, Bajpai R, Agarwal NB. Association of diabetes and hypertension with disease severity in covid-19 patients: a systematic literature review and exploratory meta-analysis. Diabetes Res Clin Pract. 2020;166:108295.

49. Wickenas et al., Hertanski FS, Ferjanda A, Pramono RB. Diabetes management and specific considerations for patients with diabetes during coronavirus diseases pandemic: a scoping review. Diabetes Metab Syndr. 2020;14(3):1109–1120.